• 学术搜索
  • 科研智能体
    • Research Labs
    • AI 阅读
    • AI 文库
    • 深度研究
    • 学者亮点
  • 学术资源
    • AI2000
    • 期刊/会议
    • 学者库
    • 学术API
      MCP&Skill
    • 溯源树
    • 数据集
  • 知识沉淀
    • 学术空间
订阅小程序
旧版功能
aminer vip
开通会员低至0.73元/天
一次搞定AI科研
立即登录
  • English
  • 联系方式
    EC ophthalmology

    EC ophthalmology

    Journal

    年发文量

    研究主题

    论文(17185)

    排序
    1Association of Common Anti-Inflammatory Medications with Reduced Risk of Vision-Threatening Diabetic Retinopathy in Type 2 Diabetes.
    Henry S Bison, Angela S Zhu,Martin Borissov, Hee-Jae Jung, Yuji Zhang,John T Thompson

    OBJECTIVE:To determine whether adults with type 2 diabetes mellitus (T2DM) using cetirizine, ibuprofen, or prednisone have a reduced incidence of diabetic macular edema (DME) and proliferative diabetic retinopathy (PDR). DESIGN:Retrospective propensity score-matched cohort study. PARTICIPANTS:Adults with T2DM and documented eye-care in the TriNetX US Collaborative Network who had two documented uses of cetirizine, ibuprofen, prednisone, fenofibrate, or gabapentin between January 1, 2005, and March 1, 2025. METHODS:Each drug cohort was 1:1 propensity score-matched on 44 covariates against non-users; fenofibrate served as a positive control, and gabapentin served as both a negative control and an active comparator. Residual confounding was assessed using eight ophthalmic negative-control outcomes (NCOs) and E-values. Nine sensitivity analyses tested comparison to users of gabapentin, alternative outcome windows, a new-user design, glycemic strata, matching for drug indication, and exposure duration. MAIN OUTCOME MEASURES:Incident DME and PDR within 3 years of the index date. RESULTS:Matched-pair counts ranged from 18,762 to 86,846. Cetirizine was associated with reduced DME (hazard ratio [HR], 0.62; 95% confidence interval [CI], 0.51-0.74) and PDR (HR, 0.59; 95% CI, 0.46-0.77); ibuprofen with reduced DME (HR, 0.63; 95% CI, 0.56-0.69) and PDR (HR, 0.48; 95% CI, 0.41-0.56); and prednisone with reduced DME (HR, 0.46; 95% CI, 0.41-0.52) and PDR (HR, 0.36; 95% CI, 0.30-0.43). Fenofibrate showed associations of similar magnitude (DME HR, 0.57; 95% CI, 0.48-0.68; PDR HR, 0.59; 95% CI, 0.45-0.77); gabapentin showed no association (DME HR, 0.95; 95% CI, 0.88-1.02; PDR HR, 1.04; 95% CI, 0.93-1.15). Point E-values for the investigational drugs ranged from 2.57 to 4.97 (lower 95% CI bound, 1.93 to 4.06). The NCO panel was near null for cetirizine and ibuprofen and showed mild protective bias for prednisone and fenofibrate. Findings persisted across the nine sensitivity analyses. CONCLUSIONS:Cetirizine, ibuprofen, and prednisone were associated with reduced incidence of DME and PDR in adults with T2DM, with effect sizes comparable to those of the fenofibrate positive control. These findings support prospective evaluation of anti-inflammatory medications for the prevention of vision-threatening diabetic retinopathy.

    2026
    引用
    AI阅读
    加入学术空间
    2Whose Advantage is It, Really?
    Nikhil Bommakanti, Jason Hsu
    2026
    引用
    AI阅读
    加入学术空间
    3Racial and Ethnic Disparities in Retinal Care Access and Experience
    Ahmed B Sallam, Muhammad Z Chauhan, Ahmed F Shakarchi, Carina T Sanvicente,Paul H Phillips

    Among 4,578 adults with DR, RVO, or eAMD in All of Us, minority participants reported more transportation, affordability, childcare, and discriminatory care experiences; disparities were greatest in DR, supporting equity-focused redesign of retinal care delivery.

    2026
    引用
    AI阅读
    加入学术空间
    4Efficacy and Safety of Satralizumab for Thyroid Eye Disease: Week 24 Results from the Phase 3 SatraGO-1 and SatraGO-2 Randomized Trials
    César A Briceño,Oluwatobi O Idowu,Jwu Jin Khong, Thomas Kuenzel, Ann Q Tran,Christopher Brittain, Atsushi Azumi, Laura Brockwell, Nima Ghadiri, Mariano Coronel, Thorsten Ruf,Dongmei Li,

    PURPOSE:To evaluate the primary efficacy and safety of satralizumab, an anti-interleukin-6 receptor antibody, in patients with thyroid eye disease (TED). DESIGN:SatraGO-1 (NCT05987423) and SatraGO-2 (NCT06106828) are identically designed, 72-week, double-masked, placebo-controlled, multicenter, 2-stage randomization phase 3 trials. PARTICIPANTS:Aged ≥18 years with active, moderate to severe TED (Clinical Activity Score [CAS] ≥3 for ≤12 months) or inactive TED (CAS <3 for ≥6 months). METHODS:Participants (SatraGO-1: N = 131; SatraGO-2: N = 127) were randomized 1:1 to receive loading doses of subcutaneous satralizumab or placebo at weeks 0, 2, and 4, followed by every-4-week dosing through week 20 (part I). MAIN OUTCOME MEASURES:The primary endpoint was the proportion of participants with active TED who achieved a proptosis response (≥2-mm reduction from baseline) at week 24. Secondary endpoints included the proportion of participants with a ≥2-point CAS reduction, disease inactivation (CAS of 0 or 1), and an ≥1-grade diplopia reduction at week 24. Efficacy outcomes were also reported for the combined active and inactive TED population. Safety was assessed in all participants exposed to study treatment. RESULTS:In participants with active TED, the satralizumab arm of both trials consistently showed an increased proportion achieving a proptosis response (SatraGO-1: 49.0% vs. 31.2%, P = 0.0715; SatraGO-2: 52.9% vs. 23.4%, P = 0.0011), CAS reduction (SatraGO-1: 78.0% vs. 54.9%, P = 0.0120; SatraGO-2: 89.6% vs. 63.3%, P = 0.0009), CAS of 0 or 1 (SatraGO-1: 68.0% vs. 45.1%, P = 0.0146; SatraGO-2: 68.8% vs. 40.8%, P = 0.0042), and diplopia reduction (SatraGO-1: 44.4% vs. 34.4%, P = 0.3371; SatraGO-2: 60.7% vs. 25.8%, P = 0.0044) vs. placebo, although not all comparisons reached statistical significance. Similar clinical benefits were observed in the combined active and inactive TED population. Satralizumab was well tolerated, with low rates of serious adverse events, treatment discontinuations, and infections, and no serious infections. CONCLUSIONS:Satralizumab demonstrated clinically meaningful improvements in proptosis, CAS, and diplopia, and had a favorable safety profile in participants with TED. Interleukin-6 pathway inhibition with subcutaneous satralizumab represents an efficacious and well-tolerated treatment option for patients with TED.

    2026
    引用
    AI阅读
    加入学术空间
    5Response to Comment on “new Intraocular Lens Power Calculation Formula for Eyes Undergoing Lens Exchange”
    Li Wang,Douglas D Koch
    2026
    引用
    AI阅读
    加入学术空间
    立即登录,查看全部 17185 篇论文

    高被引作者

    作者引用发文
    Tien Yin Wong41833145
    Ronald Klein26268106
    Paul Mitchell24289110
    Harry A. Quigley2004761
    Aung Tin18721104
    David Mark Brown1791841
    Frederick Ferris1741659
    David Boyer1729738
    Jeffrey S. Heier1662243
    Ching-Yu Cheng1597553

    高产作者

    作者引用发文
    Jerry Shields14857150
    Carol L. Shields11589147
    Tien Yin Wong41833145
    C. Stephen Foster12338119
    Robert N. Weinreb11837117
    Paul Mitchell24289110
    Ronald Klein26268106
    Aung Tin18721104
    Emily Y. Chew11487102
    David S. Friedman1064796

    相关期刊

    Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie. Albrecht von Graefe's archive for clinical and experimental ophthalmology
    Ophthalmic research
    Retina (Philadelphia, Pa.)
    Journal of glaucoma
    Ophthalmology and therapy
    Ophthalmology. Retina
    Therapeutic advances in ophthalmology
    International Journal of Retina and Vitreous
    Ophthalmologica
    Asia-Pacific journal of ophthalmology